Biblio

Found 360 results
Author Keyword Title Type [ Year(Asc)]
2006
A. du Bois, Weber, B., Rochon, J., Meier, W., Goupil, A., Olbricht, S., Barats, J. - C., Kuhn, W., Orfeuvre, H., Wagner, U., Richter, B., Lueck, H. - J., Pfisterer, J., Costa, S., Schröder, W., Kimmig, R., and Pujade-Lauraine, E., Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: a prospectively randomized gynecologic cancer intergroup trial. , J Clin Oncol, vol. 24, no. 7, pp. 1127-35, 2006.
E. Petru, Angleitner-Boubenizek, L., Reinthaller, A., Deibl, M., Zeimet, A. G., Volgger, B., Stempfl, A., and Marth, C., Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study, Gynecol Oncol, vol. 102, pp. 226-9, 2006.
G. J. S. Rustin, Timmers, P., Nelstrop, A., Shreeves, G., Bentzen, S. M., Baron, B., Piccart, M. J., Bertelsen, K., Stuart, G. C. E., Cassidy, J., and Eisenhauer, E., Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide., J Clin Oncol, vol. 24, no. 1, pp. 45-51, 2006.
C. L. Trimble, Kauderer, J., Zaino, R., Silverberg, S., Lim, P. C., ,, Alberts, D. S., and Curtin, J., Concurrent endometrial carcinoma in women with a biopsy diagnosis of atypical endometrial hyperplasia: a Gynecologic Oncology Group study, Cancer, vol. 106, pp. 812-9, 2006.
D. G. Mitchell, Snyder, B., Coakley, F., Reinhold, C., Thomas, G., Amendola, M., Schwartz, L. H., Woodward, P., Pannu, H., and Hricak, H., Early invasive cervical cancer: tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 Intergroup Study, J Clin Oncol, vol. 24, pp. 5687-94, 2006.
K. Greven, Winter, K., Underhill, K., Fontenesci, J., Cooper, J., and Burke, T., Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer, Gynecol Oncol, vol. 103, pp. 155-9, 2006.
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Lück, H. - J., Rochon, J., Zimmermann, A. Hayden, and Eisenhauer, E., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG., J Clin Oncol, vol. 24, no. 29, pp. 4699-707, 2006.
J. Pfisterer, Plante, M., Vergote, I. B., du Bois, A., Hirte, H., Lacave, A. J., Wagner, U., Stähle, A., Stuart, G. C. E., Kimmig, R., Olbricht, S., Le, T., Emerich, J., Kuhn, W., Bentley, J., Jackisch, C., Luck, H. J., Rochon, J., Zimmermann, A. Hayden, Eisenhauer, E., -OVAR, A. G. O., -CTG, N. C. I. C., and -GCG, E. O. R. T. C., Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J Clin Oncol, vol. 24, pp. 4699-707, 2006.
T. GM, S, A., M, P., O, A., and JA, III, L., A GOG phase III trial to evaluate maintaining hemoglobin = 120 G/L with erythropoietin during chemoradiation for cervical cancer. , Int J Gynecol Cancer , vol. 16, no. 3, p. 604, 2006.
P. Wimberger, Lehmann, N., Kimmig, R., Burges, A., Meier, W., Hoppenau, B., du Bois, A., and -OVAR, A. G. O., Impact of age on outcome in patients with advanced ovarian cancer treated within a prospectively randomized phase III study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR), Gynecol Oncol, vol. 100, pp. 300-7, 2006.
C. Marth, Windbichler, G. H., Hausmaninger, H., Petru, E., Estermann, K., Pelzer, A., and Mueller-Holzner, E., Interferon-gamma in combination with carboplatin and paclitaxel as a safe and effective first-line treatment option for advanced ovarian cancer: results of a phase I/II study, Int J Gynecol Cancer, vol. 16, pp. 1522-8, 2006.
D. Armstrong, Bundy, B. N., Wenzel, L. B., Huang, H., Baergen, R., Lele, S., Copeland, L., Walker, J. L., Burger, R. A., and Group, G. Oncology, Intraperitoneal cisplatin and paclitaxel in ovarian cancer, N Engl J Med, vol. 354, pp. 34-43, 2006.
H. C. Kitchener, Management of endometrial cancer., Eur J Surg Oncol, vol. 32, no. 8, pp. 838-43, 2006.
A. du Bois, Schmalfeldt, B., Meier, W., Sehouli, J., Pfisterer, J., OVAR, A. Gynaekolog, Cancer, A. G. O. Study Grou, and Onkologie, N. Gesellscha, Ovarian cancer–can intraperitoneal therapy be regarded as new standard in Germany?, Int J Gynecol Cancer, vol. 16, pp. 1756-60, 2006.
H. Bourgeois, Joly, F., Pujade-Lauraine, E., Curé, H., Guastalla, J. P., Ferru, A., Chabrun, V., Chieze, S., and Tourani, J. M., Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients, Am J Clin Oncol, vol. 29, pp. 399-404, 2006.
H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a NCIC Group Study., Gynecol Oncol, vol. 102, no. 2, pp. 300-8, 2006.
H. Hirte, Vergote, I. B., Jeffrey, J. R., Grimshaw, R. N., Coppieters, S., Schwartz, B., Tu, D., Sadura, A., Brundage, M., and Seymour, L., A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials G, Gynecol Oncol, vol. 102, pp. 300-8, 2006.
B. Gronlund, Hogdall, E. V., Christensen, I. J., Johansen, J. S., Norgaard-Pedersen, B., Engelholm, S. A., and Hogdall, C., Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125), Int J Biol Markers, vol. 21, pp. 141-8, 2006.
N. Simon Reed, Poole, C. J., Coleman, R. L., Parkin, D., Graham, J. D., Kaye, S. B., Ostrowski, J., Duncan, I., Paul, J., Hay, A., and Group, S. Gynaecolog, A randomised comparison of treosulfan and carboplatin in patients with ovarian cancer: A study by the Scottish Gynaecological Cancer Trials Group (SGCTG), Eur J Cancer, vol. 42, pp. 179-85, 2006.
A. Maggioni, P. Panici, B., Dell'Anna, T., Landoni, F., Lissoni, A., Pellegrino, A., Rossi, R. S., Chiari, S., Campagnutta, E., Greggi, S., Angioli, R., Manci, N., Calcagno, M., Scambia, G., Fossati, R., Floriani, I., Torri, V., Grassi, R., and Mangioni, C., Randomised study of systematic lymphadenectomy in patients with epithelial ovarian cancer macroscopically confined to the pelvis, Br J Cancer, vol. 95, pp. 699-704, 2006.
R. R. Barakat, Bundy, B. N., Spirtos, N. M., Bell, J. G., Mannel, R., and Study, G. Oncology G., Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study, J Clin Oncol, vol. 24, pp. 587-92, 2006.
J. G. Bell, Brady, M. F., Young, R. C., Lage, J., Walker, J. L., Look, K. Y., Rose, G. S., Spirtos, N. M., and Group, G. Oncology, Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study, Gynecol Oncol, vol. 102, pp. 432-9, 2006.

Pages